Portal de investigación
- Inicio
- Proyectos y Estudios
- SGI-110-07: ESTUDIO DE FASE III, ABIERTO, ALEATORIZADO Y MULTICÉNTRICO DE GUADECITABINA (SGI-110) EN COMPARACIÓN CON EL TRATAMIENTO DE ELECCIÓN EN ADULTOS CON SÍNDROMES MIELODISPLÁSICOS (SMD) O LEUCEMIA MIELOMONOCÍTICA CRÓNICA (LMMC) TRATADOS PREVIAMENTE CON AGENTES HIPOMETILANTES.
SGI-110-07: ESTUDIO DE FASE III, ABIERTO, ALEATORIZADO Y MULTICÉNTRICO DE GUADECITABINA (SGI-110) EN COMPARACIÓN CON EL TRATAMIENTO DE ELECCIÓN EN ADULTOS CON SÍNDROMES MIELODISPLÁSICOS (SMD) O LEUCEMIA MIELOMONOCÍTICA CRÓNICA (LMMC) TRATADOS PREVIAMENTE CON AGENTES HIPOMETILANTES.
Datos básicos
- Protocolo:
- SGI-110-07
- EUDRACT:
- 2015-005257-12
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2017
- Año de finalización:
- 2019
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A case of megaloblastic anemia simulating a cold autoimmune hemolytic anemia.
De La Puerta R; (...); Solves P
Article. 2020
A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Editorial Material. 10.1016/j.bbmt.2017.03.011. 2017
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.
Casado, MA; (...); Grp MULTIDEX-EMD
Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A NEW INTRONIC MUTATION CAUSES AN ABERRANT SPLICING IN THE ANK1 GENE
Liquori, A.; (...); Cervera, J., V
Meeting Abstract. 2018
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
Oster, HS; (...); Mittelman, M
Article. 10.1182/bloodadvances.2020004055. 2021
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
Maggioni, Giulia; (...); Della Porta, Matteo G.
Article. 10.1016/S2352-3026(22)00323-4. 2023
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 10.1016/j.leukres.2023.107226. 2023
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
Savona, Michael R.; (...); Solary, Eric
Meeting Abstract. 10.1182/blood-2019-130722. 2019
ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
Pfeilstoecker, M.; (...); Greenberg, P.
Meeting Abstract. 10.1016/j.leukres.2023.107230. 2023
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.
Montoro J; (...); Peffault de Latour R
Article. 10.1182/blood.2024024173. 2024
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Chihara D; (...); Yakoub-Agha I
Letter. 10.3324/haematol.2022.281754. 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini, Enrico; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02027-y. 2023
Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.
Article. 10.1002/ccr3.1206. 2017
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.
Esteve, Jordi; (...); Ciceri, Fabio
Article. 10.1002/ajh.27647. 2025
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
Dholaria, B; (...); Mohty, M
Article. 10.1186/s13045-021-01086-2. 2021
Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high-resolution analysis.
Guerreiro, Manuel; (...); Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
Article. 10.1111/tan.14179. 2021
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Berning, Philipp; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2022-164637. 2022
Allogeneic hematopoietic stem cell transplantation achieves long-term survival in Natural killer/T-cell lymphoma in the era of Asparaginase-based Chemotherapy
Berning, P.; (...); Glass, B.
Meeting Abstract. 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Berning, Philipp; (...); Glass, Bertram
Article. 10.1038/s41375-023-01924-x. 2023
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: EXPERIENCE OF 4 CENTERS
Benzaquen, A.; (...); Hernandez-Boluda, J. C.
Meeting Abstract. 2019
Allogeneic hsct in HIV-1 infected patients with hematological disorders: Multicenter experience from GETH (Spanish group of HSCT and cell therapy)
Kwon, M; (...); Diez-Martin, JL
Meeting Abstract. 2019
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Garderet, L; (...); Kröger N
Article. 10.1016/j.bbmt.2017.11.017. 2018
Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-144894. 2021
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-01940-6. 2023
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
Al Hamed R; (...); Mohty M
Article. 10.1038/s41409-024-02373-5. 2024
Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders
Kwon, M; (...); Grp Espanol Trasplante Hematopoyet
Article. 10.1097/QAD.0000000000002209. 2019
ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED FEATURES AS PER THE INTERNATIONAL CONSENSUS CLASSIFICATION (ICC) 2022: FROM THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2024
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
Castano-Diez, Sandra; (...); Diaz-Beya, Marina
Article. 10.1182/bloodadvances.2024013648. 2025
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian; (...); Zeidan, Amer M.
Letter. 10.1182/bloodadvances.2022008747. 2023
An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia
Shouval, Roni; (...); Nagler, Arnon
Article. 10.1158/1078-0432.CCR-17-0489. 2017
An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
Bueno F; (...); Navarro D
Article. 10.1002/jmv.26892. 2021
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions
Orti, G; (...); Valcarcel, D
Article. 10.1016/j.exphem.2018.03.002. 2018
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC/GELTAMO.
Bailen, Rebeca; (...); Kwon, Mi
Article. 10.1016/j.jtct.2024.06.022. 2024
Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study
Villalba, A; (...); Solves, P
Article. 10.1159/000488804. 2018
Antimicrobial stewardship programme implementation in a medical ward
Ruiz, J; (...); Poveda, JL
Article. 2018
Antimicrobial stewardship programme in critical care medicine: A prospective interventional study
Ruiz, J; (...); Catellanos, A
Article. 10.1016/j.medin.2017.07.002. 2018
ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY
Bug, Gesine; (...); Mohty, Mohamad
Meeting Abstract. 2023
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
Alvarez-Larran, Alberto; (...); Pereira, Arturo
Article. 10.1097/HS9.0000000000000936. 2023
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Are next-generation sequencing results knocking on Heaven's door for transplantation planning in chronic myelomonocytic leukemia?
Sanz GF, Ibañez M, Mora E
Editorial Material. 10.3324/haematol.2019.240853. 2020
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation
Perez, A; (...); Pinana, JL
Article. 10.1111/tid.13301. 2020
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Rodriguez-Veiga, R; (...); spanish PETHEMA group
Article. 10.1007/s00277-017-3004-z. 2017
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.
de la Asunción CS; (...); Navarro D
Article. 10.1002/jmv.28933. 2023
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E; (...); Papaemmanuil E
Correction. 10.1038/s41591-021-01253-5. 2021
Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Espanol De Trasplante de Medula Osea en Nimos (GETMON) and the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Gonzalez-Vicent, M; (...); Sanz, MA
Review. 10.1016/j.tmrv.2018.02.005. 2018
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M; (...); Barba P
Article. 10.3324/haematol.2022.280805. 2023
Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain
Kwon, Mi; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2021-147369. 2021
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
Diez-Campelo, M; (...); Fenaux, P
Article. 10.1111/bjh.15190. 2018
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society
Saccardi, Riccardo; (...); Snowden, John A.
Meeting Abstract. 10.1182/blood-2019-125233. 2019
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Bastos-Oreiro, Mariana; (...); Garcia-Sancho, Alejandro Martin
Article. 10.3389/fimmu.2022.855730. 2022
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC
Pena, Marta; (...); Balari, Anna Maria Sureda
Meeting Abstract. 10.1182/blood-2023-181815. 2023
BONE BIOPSY AGAINST PET/CT IN THE DETERMINATION OF MEDULAR INFILTRATION IN INITIAL STATISTICS IN FOLLICULAR LYMPHOMA: DIAGNOSTIC PRECISION AND PRONOSTIC IMPACT
Reguilon Gallego, L.; (...); Jerez Cayuela, A.
Meeting Abstract. 2019
BONE MARROW BIOPSY SUPERIORITY OVER PET/CT IN PREDICTING PROGRESSION FREE SURVIVAL IN A HOMOGENOUSLY-TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA
Liang, THC; (...); Ortuno, FJ
Meeting Abstract. 2017
Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma
Chen-Liang, TH; (...); Jose Ortuno, Francisco
Article. 10.1002/cam4.1205. 2017
Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience
Garcia-Robles, AA; (...); Fernandez-Navarro, JM
Meeting Abstract. 2017
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
Cerisoli, Francesco; (...); Hernandez Rivas, Jesus Maria
Article. 10.1016/j.jval.2022.04.1729. 2022
CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model
Ferrer Lores, Blanca; (...); Jose Terol, Maria
Meeting Abstract. 10.1182/blood-2023-185088. 2023
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Madry, Krzysztof; (...); Smith, Alex
Article. 10.1111/bjh.18542. 2022
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Circulating megakaryocyte in primary myelofibrosis. An uncommon finding in a myelofibrosis blood smear.
Cantó PA, Peris MLS, Castera EM
Editorial Material. 10.5045/br.2021.2020269. 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M; (...); Della Porta MG
Article. 10.1200/JCO.20.01659. 2021
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; (...); Zeidan AM
Article. 10.1016/j.blre.2023.101128. 2023
Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2021-152678. 2021
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Nomdedeu, M; (...); Spanish MDS Group
Article. 10.1016/j.leukres.2017.10.011. 2017
Clinical and biological significance of Y chromosome loss in a series of 2,423 male patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia
Costa, D.; (...); Campo, E.
Meeting Abstract. 2018
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; (...); Della Porta MG
Article. 10.1200/JCO.23.02175. 2024
CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
Calvete, O.; (...); Sole, F.
Meeting Abstract. 10.1016/j.leukres.2023.107176. 2023
Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia
Gil-Manso, Rodrigo; (...); Alvarez-Larran, Alberto
Meeting Abstract. 10.1182/blood-2023-188875. 2023
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.
Muntañola A; (...); Bosch F
Letter. 10.1186/s40164-020-00195-x. 2020
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study
Pinana, JL; (...); Navarro, D
Article. 10.1093/cid/ciy792. 2019
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
Riva, Elena; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-166050. 2022
Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study
Sanz, Jaime; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-147296. 2021
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Bazarbachi, A; (...); Mohty, M
Article. 10.3324/haematol.2019.243410. 2020
Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens.
Piñana JL; (...); Navarro D
Letter. 10.1016/j.jinf.2020.01.001. 2020
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS
Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel
Meeting Abstract. 2021
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I; (...); Cervantes F
Article. 10.1016/j.medcli.2019.11.007. 2020
Clonal Cytopenias and Oligoblastic Myelogenous Leukemia (myelodysplasia) Have Neoplastic, not Hyperplastic, Erythropoiesis Reply
Arenillas, L; (...); Florensa, L
Letter. 10.1200/JCO.2016.71.3941. 2017
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice
Chiusolo, Patrizia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182831. 2023
Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation
Stiff, PJ; (...); Sanz, G
Article. 10.1016/j.bbmt.2018.02.012. 2018
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.
Montoro J; (...); Piñana JL
Article. 10.1038/s41409-020-0943-0. 2020
Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections
Pinana, JL; (...); Navarro, D
Article. 10.1111/tid.12926. 2018
COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA
Valenzuela, AV; (...); Ramos, IJ
Meeting Abstract. 2018
Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki, Eleni; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-146303. 2021
Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide
Piemontese, Simona; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182923. 2023
Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT
Kharfan-Dabaja, MA; (...); Mohty, M
Article. 10.1038/s41409-021-01317-7. 2021
Comparison between Two Protocols for Platelet Transfusion in Patients Undergoing ABO Incompatible Hematopoietic Stem Cell Transplantation
Carpio, N; (...); Sanz, M
Meeting Abstract. 2018
Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization
Xicoy, B; (...); Tzu, HCL
Meeting Abstract. 10.1182/blood-2018-99-111883. 2018
COMPARISON OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA WITH AND WITHOUT AUTOINMUNE DISEASE
Moreno, AT; (...); Santillana, GS
Meeting Abstract. 2018
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 2021
Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Post-transplant Cyclophosphamide in Patients with Acute Leukemia.
Nagler A; (...); Mohty M
Article. 10.1158/1078-0432.CCR-20-2809. 2020
Comparison of Haploidentical Peripheral Blood Cell Transplantation Using Post-Transplant Cyclophosphamide With Double Cord Blood Transplantation in Adults With Acute Leukemia
Ruggeri, A; (...); Mohty, M
Meeting Abstract. 2021
Comparison of Matched Sibling, Unrelated and Haploidentical Donor Transplants Using Post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia, a Study of the ALWP EBMT
Sanz, Jaime; (...); Mohty, Mohamad
Meeting Abstract. 2020
Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT.
Ruggeri, Annalisa; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.07.006. 2022
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
Complex aortopulmonary window. On purpose of 3 cases
Martinez, FS; (...); Leon, JM
Article. 10.1016/j.circv.2020.11.007. 2021
CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
CONDITIONING INTENSITY IN STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2024
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
Zeidan, Amer M.; (...); Fenaux, Pierre
Article. 10.1182/blood.2022018604. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Aakash, Fnu; (...); Loghavi, Sanam
Article. 10.1016/j.modpat.2024.100615. 2024
CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION
Hua, Chen-Liang Tzu; (...); Andres, Jerez
Meeting Abstract. 2021
Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome
Villalba, A; (...); Senent, L
Letter. 10.1007/s00277-018-3334-5. 2018
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe, Mizuki; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2023010598. 2024
CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1111/bjh.19130. 2023
Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission
Baron, F; (...); Nagler, A
Article. 10.1111/joim.12870. 2019
Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists.
Stojkov, Igor; (...); Stauder, Reinhard
Article. 10.1182/bloodadvances.2021004568. 2021
Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem- AR): demographics, complications, and management of patients with ß-thalassemia.
Bardón-Cancho EJ; (...); Cela E
Correction. 10.1007/s00277-024-05838-1. 2024
Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A; (...); Mohty M
Correction. 10.1038/s41409-020-0835-3. 2020
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Correction. 10.1038/s41409-023-01967-9. 2023
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1080/13696998.2017.1311903. 2017
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN
Trillo, JL; (...); Torres, C
Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018
Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
Camara, R; (...); Grau, S
Article. 10.1007/s12325-017-0600-1. 2017
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Grau, S; (...); Gozalbo, I
Article. 10.1007/s10198-017-0907-5. 2018
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre
Moreno, D; (...); Carpio, N
Meeting Abstract. 2021
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.
Article. 10.1016/j.blre.2023.101072. 2023
Current management of patients with chronic myelomonocytic leukemia
Review. 10.1097/CCO.0000000000000486. 2018
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alotaibi, Shaykhah; (...); Aljurf, Mahmoud
Article. 10.1016/j.clml.2022.02.008. 2022
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?
Bueno F; (...); Navarro D
Article. 10.1111/tid.13440. 2020
Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1016/j.cmi.2023.05.010. 2023
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1111/bjh.17732. 2021
Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion
Lara, SH; (...); Suarez-Varela, MM
Article. 10.1007/s00408-018-0186-7. 2019
Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae
Rechenberger, J; (...); Kuster, B
Article. 10.3390/proteomes7010002. 2019
Changes in nutritional status, body composition and associated symptomatology in hospitalized patients undergoing bone marrow transplantation: prospective longitudinal study
Cabanas-Alite, L; (...); Pinana, LL
Article. 10.14306/renhyd.25.2.1098. 2021
CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION
Liquori, A.; (...); Gomez-Segui, I
Meeting Abstract. 2019
CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1
Marco Ayala, J.; (...); Sanz, G.
Meeting Abstract. 2019
CHARACTERIZATION OF MUTATIONS ALTERING THE PROCESS OF SPLICING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2018
CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"
Alessandro, Liquori; (...); Zamora Jose, Cervera
Meeting Abstract. 2020
CHOOSING THE APPROPRIATE DENOMINATOR FOR COUNTING BM BLASTS
Arenillas, L; (...); Florensa, L
Meeting Abstract. 10.1016/S0145-2126(17)30121-2. 2017
CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE
Nomdedeu, M; (...); Haase, D
Meeting Abstract. 10.1016/S0145-2126(17)30161-3. 2017
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Caballero JC; (...); Díez Campelo M
Article. 10.1007/s00277-019-03751-6. 2019
Chronic Myelomonocytic Leukemia ( CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss
Castano-Diez, Panelsandra; (...); Diaz-Beya, Marina
Meeting Abstract. 10.1182/blood-2023-173311. 2023
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Vincent, Laure; (...); Beksac, Meral
Letter. 10.1038/s41409-021-01560-y. 2022
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS; (...); Della Porta MG
Article. 10.1016/S2352-3026(24)00251-5. 2024
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
Blade, J; (...); Lizan, L
Article. 10.1136/bmjopen-2017-018850. 2018
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain
Lalaoui, R; (...); Rolain, JM
Article. 10.1016/j.jiac.2019.03.007. 2019
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I; (...); Siebert U
Article. 10.1182/bloodadvances.2022008360. 2023
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Hernández-Boluda JC; (...); Yakoub-Agha I
Article. 10.1038/s41375-020-0815-z. 2020
Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Study by the Chronic Malignancies Working Party of EBMT
Hernandez-Boluda, JC; (...); Yakoub-Agha, I
Meeting Abstract. 2020
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.
Shouval R; (...); Nagler A
Article. 10.1016/S2352-3026(20)30394-X. 2021
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY
Romero, EG; (...); Zamora, JVC
Meeting Abstract. 2017
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
Rochau U; (...); Stauder R
Article. 10.1111/bjh.16654. 2020
DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Liquori, A.; (...); Zamora, JVC
Meeting Abstract. 2017
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults Recommendations From the European Hematology Association and the European LeukemiaNet
Itzykson, R; (...); European LeukemiaNet
Article. 10.1097/HS9.0000000000000150. 2018
DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA
Marco Ayala, J.; (...); Sanz, M. A.
Meeting Abstract. 2018
Differential diagnosis of myelodysplastic syndrome: anemia associated with copper deficiency
Villalba, A, Senent, L
Editorial Material. 10.1182/blood-2017-11-818013. 2018
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Miyazaki, Y; (...); Greenberg, PL
Article. 10.1016/j.leukres.2018.08.022. 2018
Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke
Puig, J; (...); Pedraza, S
Review. 10.1007/s00234-017-1816-0. 2017
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Santini, Valeria; (...); Zeidan, Amer M.
Meeting Abstract. 10.1182/blood-2022-160282. 2022
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Article. 10.1182/bloodadvances.2019000680. 2019
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.
Meeting Abstract. 10.1182/blood-2021-150766. 2021
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
Pfeilstocker, Michael; (...); Greenberg, Peter L.
Meeting Abstract. 10.1182/blood-2022-158671. 2022
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
Itzykson, R; (...); European MDS Registry Members
Article. 10.1182/bloodadvances.2018020495. 2018
Economic Burden of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Spanish Multicenter, Retrospective Study
Vazquez, L; (...); Solano, C
Meeting Abstract. 2020
Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan
Ribera, E; (...); Hernandez-Novoa, B
Article. 10.1016/j.eimc.2016.11.015. 2018
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA
Morote-Faubel, M.; (...); Cervera, J.
Meeting Abstract. 2019
EFFECTIVENESS AND SAFETY OF THE INFUSION OF DONOR LYMPHOCYTES AFTER HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOYETIC PROGENITOR CELLS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: MULTICENTRIC RETROSPECTIVE STUDY OF THE HEMATOPETIC SPANISH TRIPASHOLE GROUP
Martin-Sanchez, Guillermo; (...); Bermudez, Aranzazu
Meeting Abstract. 2020
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group
Pleyer, Lisa; (...); Greil, Richard
Meeting Abstract. 10.1182/blood-2019-123941. 2019
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; (...); Chen YB
Article. 10.1016/S2352-3026(21)00367-7. 2022
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301) : a randomised, multicentre, double-blind, phase 3 trial
Zeiser, Robert; (...); Chen, Yi-Bin
Article. 10.1016/S2352-3026(21)00367-7. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Ferra, Christelle; (...); Baltasar, Patricia
Meeting Abstract. 10.1182/blood-2022-162186. 2022
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study
Baltasar, Patricia; (...); Ferra, Christelle
Meeting Abstract. 10.1182/blood-2021-147685. 2021
Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial
Perez-Lamas, Lucia; (...); Garcia Gutierrez, Valentin
Meeting Abstract. 10.1182/blood-2023-184989. 2023
EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY
Martin, EMD; (...); Castera, MJT
Meeting Abstract. 2018
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
Calvo, X; (...); Florensa, L
Article. 10.1002/ajh.24732. 2017
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
Garelius, HKG; (...); Hellström-Lindberg E
Article. 10.1111/joim.12579. 2017
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1038/s41409-023-02075-4. 2023
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies
Paviglianiti, A; (...); Rocha, V
Article. 10.1111/bjh.14962. 2017
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2022-168718. 2022
EVALUATION OF THE EFFICACY AND SAFETY OF NILOTINIB 300 BID IN SECOND LINE AFTER IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
Garcia Gutierrez, V; (...); Steegmann, J. L.
Meeting Abstract. 2019
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
Bazarbachi A; (...); Mohty M
Article. 10.1158/1078-0432.CCR-20-3134. 2020
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro, Juan; (...); Sanz, Jaime
Article. 10.1111/ejh.13529. 2021
Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death
Madry, K; (...); Smith, A
Meeting Abstract. 10.1182/blood-2018-99-115928. 2018
Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
del Pozo, Victoria; (...); Rua-Figueroa, Inigo
Review. 10.3389/fimmu.2023.1310211. 2024
EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A GLOBAL MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: PRELIMINARY RESULTS FROM THE HLALOSS COLLABORATIVE STUDY
Vago, Luca; (...); Fleischhauer, Katharina
Meeting Abstract. 2018
Exploiting Cutting-Edge Technologies to Analyze Loss of HLA in a Global Multicentric Cohort of Post-Transplantation Relapses: Preliminary Results from the HLALOSS Collaborative Study
Vago, Luca; (...); Fleischhauer, Katharina
Meeting Abstract. 2018
EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY
Vago, L.; (...); Fleischhauer, K.
Meeting Abstract. 2018
Exploratory analysis for the implementation of antineoplastic logarithmic dose banding
Albert-Mari, A; (...); Poveda-Andres, JL
Article. 10.1007/s11096-018-0714-9. 2018
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.
Canto, Pedro Asensi; (...); Segui, Ines Gomez
Article. 10.1016/j.jtct.2023.07.001. 2023
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation
Solves P; (...); Carpio N
Article. 10.1007/s00277-017-3168-6. 2018
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis
Fox, ML; (...); Valcarcel, D
Article. 10.1080/10428194.2020.1788015. 2020
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Hernandez-Boluda, JC; (...); GELMC
Article. 10.1038/s41408-018-0125-0. 2018
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Espanol De Trasplante y Terapia Celular (GETH-TC) Study
Fabbri, Nicole; (...); Mussetti, Alberto
Meeting Abstract. 10.1182/blood-2023-185721. 2023
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, Amer M.; (...); Santini, Valeria
Article. 10.1038/s41375-022-01724-9. 2022
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2024-204672. 2024
FREQUENCY AND IMPACT OF SOMATIC MUTATIONS ON OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 2024
Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Garcia Cadenas, Irene; (...); Solano, Carlos
Meeting Abstract. 2018
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran
Article. 10.1111/ejh.13226. 2019
FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 2020
FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS
De Matteo, B; (...); Zamora, JVC
Meeting Abstract. 2017
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
D'Amico, Saverio; (...); Della Porta, Matteo Giovanni
Meeting Abstract. 10.1182/blood-2024-209541. 2024
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E.; (...); Papaemmanuil, E.
Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023
Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain
Lalaoui, R; (...); Rolain, JM
Article. 10.1186/s13756-019-0630-3. 2019
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.
Alvarez-Larrán A; (...); Hernández-Boluda JC
Letter. 10.1038/s41375-020-0849-2. 2020
Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction
Chen-Liang, TH; (...); Jerez, A
Meeting Abstract. 10.1182/blood-2018-99-116045. 2018
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT
Montesinos, Pau; (...); Delgado, Julio
Meeting Abstract. 2018
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
Roboz GJ; (...); Döhner H
Article. 10.1182/bloodadvances.2023012062. 2024
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12568. 2017
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/bloodadvances.2023012133. 2024
Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Non-Hodgkin Lymphoma: The Spanish Experience
Dorado, N; (...); Kwon, M
Meeting Abstract. 2020
Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis
Gagelmann, N; (...); Kroger, N
Review. 10.1001/jamaoncol.2019.3541. 2019
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000790. 2022
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-144558. 2021
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus
Meeting Abstract. 10.1182/blood-2021-149521. 2021
Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study
Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units
Article. 10.7399/fh.10935. 2018
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
Stauder, R; (...); de Witte, T
Article. 10.1038/s41375-018-0089-x. 2018
HEALTH-RELATEDQUALITYOF LIFE IS SUBSTANTIALLY IMPAIRED IN LOWER-RISK MDS WHEN COMPARED WITH REFERENCE POPULATIONS AND SIGNIFICANTLY AFFECTS OVERALL SURVIVAL
Stauder, R; (...); De Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30135-2. 2017
Hematopoietic Stem cell transplant in Aplastic anemia in patients older than 40 years: The experience of the Spanish Group of Hematopoietic Stem Cell Transplant (GETH)
Yanez, Lucrecia; (...); Solano, Carlos
Meeting Abstract. 2018
Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.
Sanz, Jaime; (...); Marrow Transplantation (EBMT)
Article. 10.1038/s41409-020-01162-0. 2020
Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.
Ruggeri A; (...); Nagler A
Article. 10.1038/s41409-019-0582-5. 2019
High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$-Lactams.
Djukovic, Ana; (...); Ubeda, Carles
Article. 2020
High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.
Djukovic A; (...); Ubeda C
Article. 10.1128/AAC.01415-19. 2020
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1002/ajh.27466. 2024
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke
Puig, J; (...); Castellanos, M
Article. 10.1371/journal.pone.0188238. 2017
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Human Mesenchymal Stem Cells Growth and Osteogenic Differentiation on Piezoelectric Poly(vinylidene fluoride) Microsphere Substrates
Sobreiro-Almeida, R.; (...); Sempere, A.
Article. 10.3390/ijms18112391. 2017
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta, Pau; (...); Bosch, Francesc
Article. 10.1016/j.eclinm.2024.102642. 2024
IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP
Rey, Bua Beatriz; (...); Martin, A.
Meeting Abstract. 2020
Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in Spain.
Giraldo P; (...); Morales-Conejo M
Article. 10.1016/j.medcli.2024.06.006. 2024
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
Imaging features and clinical data-based network analysis of CAR-T treated B- cell lymphoma patients in relation to their TP53 mutation status
Estepa-Fernandez, A.; (...); Alberich-Bayarri, A.
Meeting Abstract. 2024
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.
Szabolcs, Paul; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.04.018. 2023
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
de la Asuncion Carlos, Solano; (...); Navarro, David
Letter. 10.1111/bjh.18655. 2023
Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch.
Santiago, M; (...); Solves, P
Letter. 10.1111/tme.12538. 2019
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis
Edo Solsona MD; (...); Poveda Andrés JL
Article. 10.2147/PPA.S127508. 2017
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
Impact of an antimicrobial stewardship program on critical haematological patients.
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.7399/fh.2017.41.4.10709. 2017
IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2023
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.08.018. 2022
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
Matteuzzi, Tommaso; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-152215. 2021
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1111/bjh.18765. 2023
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Torrent, Anna; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-186388. 2023
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.
de Swart L; (...); EUMDS Registry Participants
Article. 10.3324/haematol.2018.212217. 2020
IMPACT OF RED BLOOD CELL TRANSFUSIONS ON SURVIVAL IN LOWER-RISK MDS PATIENTS INCLUDED IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY
de Swart, L; (...); de Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30393-4. 2017
Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.
Oreiro MB; (...); García-Sancho AM
Article. 10.1016/j.jtct.2023.08.026. 2023
Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
Bastos-Oreiro, Mariana; (...); Martin Garcia-Sancho, Alejandro
Meeting Abstract. 10.1182/blood-2022-166329. 2022
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.
Pastor-Galan, Irene; (...); Hernandez-Boluda, Juan Carlos
Article. 10.1038/s41375-024-02389-2. 2024
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER
Marco, Ayala Javier; (...); Solves, Alcaina Pilar
Meeting Abstract. 2020
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; (...); EUMDS Registry Participants
Article. 10.3324/haematol.2018.212332. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2017
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1159/000478969. 2018
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, Elsa; (...); Elias, Harold K
Article. 10.1038/s41591-021-01367-w. 2021
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard, E; (...); Papaemmanuil, E
Article. 10.1038/s41591-020-1008-z. 2020
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2018
IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra
Meeting Abstract. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; (...); Díaz TM
Article. 10.1002/cam4.6300. 2023
Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study
Vago, L; (...); Fleischhauer, K
Meeting Abstract. 10.1182/blood-2018-99-112142. 2018
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2022-162397. 2022
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients
Pinana, JL; (...); Navarro, D
Article. 10.1111/tid.13158. 2019
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN THE ALOGENIC TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS
Balaguer Rosello, A.; (...); Sanz Caballer, J.
Meeting Abstract. 2018
INFECTIOUS EVENTS DURING TREATMENT WITH HYPOMETHYLATING AGENTS WORSE THE PROGNOSIS AND QUALITY OF LIFE OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOBLASTIC LEUKEMIA (LAM), A STUDY OF THE GESM
Vilorio-Marques, Laura; (...); Bernal, Teresa
Meeting Abstract. 2020
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.
Ruiz J; (...); Poveda JL
Article. 10.23736/S0026-4946.18.04978-2. 2018
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Polymorphisms Related to Drug Metabolism in Allogeneic Bone Marrow Transplantation
Santiago, M; (...); Alino, S
Meeting Abstract. 2021
IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2019
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
Mosquera-Orgueira, Adrian; (...); Hernandez-Boluda, Juan C.
Letter. 10.1002/hem3.60. 2024
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
Blanes, M; (...); de la Rubia, J
Letter. 10.1007/s00277-019-03663-5. 2019
Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019
Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen
Montoro, J; (...); Pinana, JL
Article. 10.1111/ejh.13202. 2019
INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION
Montoro, J.; (...); Pinana, J. L.
Meeting Abstract. 2018
Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)
Fleischhauer, K; (...); Vago, L
Meeting Abstract. 2018
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
Im, Annie; (...); Pavletic, Steven Z.
Meeting Abstract. 10.1182/blood-2022-169605. 2022
Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation.
Bueno F; (...); Navarro D
Article. 10.1111/tid.13507. 2020
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.
Cruz, David; (...); Gallardo, David
Article. 10.3389/fimmu.2023.1066393. 2023
Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
Marco-Ayala, J; (...); Peris, MLS
Editorial Material. 10.5045/br.2020.2020059. 2020
Live donor kidney transplantation. Situation analysis and roadmap.
de la Oliva Valentín M; (...); Domínguez-Gil B
Article. 10.1016/j.nefroe.2022.02.002. 2022
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gomez, E; (...); Fernandez-Rodriguez, C M
Article. 10.1111/apt.18004. 2024
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02012-5. 2023
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-156231. 2022
Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP
Michallet, M; (...); Yakoub-Agha, I
Meeting Abstract. 2019
Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
de Koning, Coco; (...); Nierkens, Stefan
Article. 10.1038/s41409-021-01417-4. 2021
LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167138. 2022
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.
Mosquera Orgueira, Adrian; (...); Valcarcel, David
Article. 10.1097/HS9.0000000000000961. 2023
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
Mosquera Orgueira, Adrian; (...); Hernandez Boluda, Juan Carlos
Meeting Abstract. 10.1182/blood-2022-158669. 2022
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Mosquera-Orgueira A; (...); Hernández-Boluda JC
Article. 10.1097/HS9.0000000000000818. 2023
Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2023-183029. 2023
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F; (...); Pleyer L
Article. 10.1182/blood.2023023476. 2024
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
Bowen, David; (...); de Witte, Theo M.
Meeting Abstract. 10.1182/blood-2021-150322. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Smoljanovic, Inga Mandac; (...); Bowen, David
Meeting Abstract. 10.1182/blood-2022-167716. 2022
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Brissot E; (...); Mohty M
Article. 10.1038/s41409-020-0970-x. 2020
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C; (...); Passamonti F
Article. 10.1016/j.esmoop.2022.100403. 2022
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
MATCHED RELATED VERSUS MATCHED UNRELATED VERSUS HAPLOIDENTICAL DONORS IN FLT3-ITD + AML PATIENTS IN CR1: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
Brissot, Eolia; (...); Ciceri, Fabio
Meeting Abstract. 2024
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination
Oster, HS; (...); Mittelman, M
Meeting Abstract. 10.1182/blood-2018-99-111838. 2018
Measurable Residual Disease (MRD) Testing for Acute Leukemia in EBMT Transplant Centers: A Survey on Behalf of The ALWP of the EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2020
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-020-01005-y. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-186293. 2023
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko, Maria; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023723. 2024
MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING
Navarro, MB; (...); Cervera, J
Meeting Abstract. 2017
MOLECULAR CHARACTERIZATION OF PATIENTS WITH HEREDITARY MYELOID NEOPLASIAS THROUGH MASS SEQUENCING
Pardo-Lorente, N.; (...); Cervera, J.
Meeting Abstract. 2018
MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2020
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-186863. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Bernard, Elsa; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023727. 2024
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.
Fernandez-Megia, MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.10793. 2018
Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target
Medina, Daniel; (...); Crespo, Marta
Meeting Abstract. 10.1182/blood-2023-185683. 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
Ramos, F; (...); Spanish Group for Myelodysplastic Syndromes (GESMD)
Article. 10.1002/ajh.24813. 2017
Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases
Artacho, Alejandro; (...); Ubeda, Carles
Article. 10.1186/s40168-024-01948-0. 2024
MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES
Papanicolaou, Genovefa; (...); Hirji, Ishan
Meeting Abstract. 2023
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
MUTATIONAL PROFILE IN PATIENTS DIAGNOSED WITH LOW-RISK SMD WITHOUT THE RINGED SIDEROBLASTS
Abaigar, M; (...); Campelo, MD
Meeting Abstract. 2018
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
Cedena, MT; (...); Martinez-Lopez, J
Article. 10.18632/oncotarget.22157. 2017
Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
Hayashi H; (...); Eurocord, Cellular Therapy & Immunobiology Working Party, and Paediatric Disease
Article. 10.1016/j.bbmt.2019.07.031. 2019
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; (...); Tormo, M
Article. 10.1111/bjh.17675. 2021
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P; (...); ESMO Guidelines Comm
Article. 10.1016/j.annonc.2020.11.002. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II.
Musri, Melina Mara; (...); Sanchez, Mayka
Article. 10.3390/ijms24129935. 2023
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial
Horwitz, ME; (...); Sanz, G
Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018
Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
Balaguer-Rosello, A; (...); Sanz, Jaime
Article. 10.1016/j.bbmt.2019.05.024. 2019
Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2019
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-021-01537-x. 2022
Non-T Depleted Haploidentical Stem Cell Transplantation in Aml Patients Achieving First Complete Remission After One Vs Two Induction Courses: A Study From The ALWP/EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2021
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1186/s13045-023-01450-4. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)
Nagler, Arnon; (...); Mohty, Mohamad
Correction. 10.1186/s13045-023-01501-w. 2023
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.
De Witte T; (...); Smith A
Article. 10.3324/haematol.2020.266817. 2020
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
OLD MATCHED SIBLING DONOR VERSUS YOUNG HAPLOIDENTICAL DONOR FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TRANSPLANTED IN FIRST REMISSION
Poire, Xavier; (...); Ciceri, Fabio
Meeting Abstract. 2024
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
Piemontese S; (...); Ciceri F
Article. 10.1038/s41375-024-02359-8. 2024
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz, ME; (...); Sanz, G
Article. 10.1182/blood.2021011719. 2021
One or two umbilical cord blood cell units? Caveat emptor
Sanz J, Gale RP
Article. 10.1038/bmt.2016.277. 2017
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies.
Bogliolo M; (...); Surralles J
Article. 10.1136/jmedgenet-2019-106249. 2020
OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2019
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Optimizing Outcomes of Acute Leukemia After Transplants with Single Unrelated Cord Blood Units Selected According to Current International Recommendations for Cell Dose and HLA Match
Rafii, H; (...); Gluckman, E
Meeting Abstract. 2020
Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT
Heinicke, Thomas; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-174233. 2023
Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.
Perez, Ariadna; (...); Pinana, Jose Luis
Article. 10.1007/s15010-024-02213-0. 2024
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Park, Sophie; (...); Fenaux, Pierre
Letter. 10.1016/j.leukres.2020.106472. 2020
OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS
Park, S; (...); Fenaux, P
Meeting Abstract. 10.1016/S0145-2126(17)30162-5. 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Park S; (...); Fenaux P
Article. 10.1200/JCO.2016.71.3271. 2017
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero, Juan Carlos; (...); Diez Campelo, Maria
Article. 10.1177/20406207231218157. 2024
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socie, Gerard; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02127-9. 2024
OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 2023
Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study
Perez-Lamas, Lucia; (...); Gutierrez, Valentin Garcia
Meeting Abstract. 10.1182/blood-2023-187412. 2023
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin
Article. 10.1007/s00277-024-05906-6. 2024
Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
Baron F; (...); Mohty M
Article. 10.1038/s41409-023-02000-9. 2023
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; (...); Greil R
Article. 10.1016/S2352-3026(20)30374-4. 2021
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii, Hanadi; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2022007941. 2022
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY
Lang, K.; (...); Bullinger, L.
Meeting Abstract. 2023
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-157549. 2022
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-145002. 2021
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Hernández-Boluda JC; (...); Cervantes F
Letter. 10.1038/leu.2017.297. 2018
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 10.1182/blood-2018-99-119430. 2018
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Roboz, Gail J.; (...); Wei, Andrew H.
Letter. 10.1080/10428194.2021.2012667. 2022
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide
Horwitz, ME; (...); Sanz, G
Article. 10.1200/JCO.18.00053. 2019
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
POOLED FECAL ALLOGENEIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUSHOST DISEASE: RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE
Malard, Florent; (...); Mohty, Mohamad
Meeting Abstract. 2024
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Meeting Abstract. 2023
Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC.
Bailen, Rebeca; (...); Kwon, Mi
Article. 10.1016/j.jtct.2022.01.020. 2022
Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC
Bailen, Rebeca; (...); Kwon, Mi
Meeting Abstract. 10.1182/blood-2021-150835. 2021
Post-transplant Cyclophosphamide after Matched Sibling and Matched Unrelated Compared to Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Study on Behalf of Geth
Kwon, M; (...); Martin, JLD
Meeting Abstract. 2020
Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT
Sanz, Jaime; (...); Nagler, Arnon
Meeting Abstract. 10.1182/blood-2019-125859. 2019
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp
Article. 10.1186/s13045-020-00882-6. 2020
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Sanz, J; (...); Mohty, M
Article. 10.1186/s13045-021-01094-2. 2021
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; (...); Díez-Martín JL
Article. 10.1007/s00277-020-04317-7. 2020
Post-transplant cyclophosphamide for GVHD prophylaxis in matched unrelated donor transplantation
Bailen, R; (...); Kwon, M
Meeting Abstract. 2019
Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis
Bailen, Rebeca; (...); Luis Diez-Martin, Jose
Meeting Abstract. 10.1182/blood-2019-124849. 2019
Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
Wieczorek, Michele; (...); Mohty, Mohamad
Letter. 10.1002/ajh.26782. 2022
Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT
Wieczorek, Michele; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-151087. 2021
Post-transplant cyclophosphamide separates graft-versus host disease (GVHD) and graft versus leukemia (gvl) effects after HLA- matched stem-cell transplantation (sct) for AML
Shimoni, A.; (...); Mohty, M.
Meeting Abstract. 2022
Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Battipaglia, Giorgia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2024-207391. 2024
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel, Sebastian; (...); Mohty, Mohamad
Article. 10.1002/cncr.35004. 2023
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
Brissot, E; (...); Mohty, M
Article. 10.1186/s13045-020-00923-0. 2020
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with all treated in CR1 with allo-HCT from matched unrelated donors. A study from ALWP of the EBMT
Giebel, S.; (...); Mohty, M.
Meeting Abstract. 2022
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Article. 10.1002/cncr.35365. 2024
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi, Firoozeh; (...); Schonland, Stefan
Article. 10.1016/j.jtct.2021.09.008. 2021
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro, Juan; (...); Glass, Bertram
Article. 10.1016/j.jtct.2023.11.021. 2024
Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Abou Dalle, Iman; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-187095. 2023
Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process
Valero, S; (...); Poveda, JL
Article. 10.1016/j.yrtph.2018.03.001. 2018
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters
Herrera Lara S; (...); Morales Suárez-Varela M
Article. 10.1007/s00408-017-0032-3. 2017
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Hernández-Boluda JC; (...); Piñana JL
Article. 10.1016/j.bbmt.2020.07.022. 2020
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model
Ferrer-Lores, Blanca; (...); Alberich-Bayarri, Angel
Article. 10.1186/s13550-024-01172-9. 2024
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 2017
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
Abrisqueta, Pau; (...); Bosch, Francesc
Meeting Abstract. 10.1182/blood-2019-128470. 2019
Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
Goetze, Katharina S. S.; (...); Platzbecker, Uwe
Meeting Abstract. 2024
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-182823. 2023
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2018
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.
Kanda J; (...); Gluckman E
Article. 10.1038/s41375-019-0534-5. 2020
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS
de Swart, L; (...); de Witte, T
Article. 10.1016/j.leukres.2018.01.022. 2018
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
Martin, I; (...); Sanz, G
Article. 10.1038/s41408-017-0016-9. 2017
Prognostic risk models for transplant decision-making in myelofibrosis
Hernandez-Boluda, JC; (...); Cervantes, F
Article. 10.1007/s00277-018-3240-x. 2018
PROGNOSTIC VALUE OF EARLY DROP IN PLATELETS IN LOWER-RISK MDS. A SUB-STUDY FROM THE EUROPEAN LEUKEMIANET LOWER-RISK MDS (EUMDS) REGISTRY
Itzykson, R; (...); de Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30132-7. 2017
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; (...); Orfao A
Article. 10.1016/S2352-3026(20)30400-2. 2021
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.10.014. 2020
Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1097/DSS.0000000000001046. 2017
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT.
Montoro J; (...); Glass B
Article. 10.1182/bloodadvances.2024013328. 2024
Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
Pinana, JL; (...); Navarro, D
Article. 10.1016/j.jinf.2019.02.009. 2019
Pulmonary invasive fungal disease after community acquire respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients: Results from a prospective observational study
Pinana, Jose; (...); Navarro, David
Meeting Abstract. 2019
Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.
Marco-Ayala J; (...); Solves P
Review. 10.1038/s41409-020-01124-6. 2021
Purtscher-like retinopathy associated with dermatomyositis and hemophagocytic lymphohistiocytosis.
Barreiro-González A; (...); Azorín Villena I
Article. 10.1016/j.oftal.2017.03.009. 2018
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem
Meeting Abstract. 2023
RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.; (...); Yacoub, A.
Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023
Rapid and Robust CD4+and CD8+T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Boelens, JJ; (...); Nierkens, S
Meeting Abstract. 10.1182/blood-2018-99-116700. 2018
Rapid and Robust CD4+and CD8+T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
de Koning, Coco; (...); Boelens, Jaap-Jan
Meeting Abstract. 2019
Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
Serrano-Gonzalo, Irene; (...); Giraldo, Pilar
Article. 10.1186/s13023-023-02939-4. 2023
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Luna, A.; (...); Garcia-Gutierrez, V
Article. 10.1007/s00277-022-04932-6. 2022
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
Sauta, Elisabetta; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-163634. 2022
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni
Article. 10.1200/JCO.22.01784. 2023
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernandez-Sanchez, Alberto; (...); Bullinger, Lars
Article. 10.1038/s41375-024-02333-4. 2024
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167480. 2022
Recent advances in allogeneic transplantation for acute myeloid leukemia.
Montoro J, Balaguer-Roselló A, Sanz J
Article. 10.1097/CCO.0000000000000992. 2023
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A; (...); Mohty M
Article. 10.1038/s41409-020-0803-y. 2020
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reduced Intensity (RIC) vs Myeloablative Conditioning (MAC) in Cord Blood Transplantation for AML (40-60 Years) Across Mismatched HLA Barriers - Analysis by Ctiwp/eurocord of EBMT
Sheth, V; (...); Ruggeri, A
Meeting Abstract. 2020
Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.
Sheth V; (...); Ruggeri A
Article. 10.1016/j.bbmt.2020.07.025. 2020
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Bastos-Oreiro M; (...); López-Guillermo A
Article. 10.1007/s00277-020-03918-6. 2020
REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?
Santiago, Marta; (...); Cervera, Jose
Meeting Abstract. 2020
RESPONSE TO AZACITIDINE IN A SERIES OF 94 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES
Triguero, A; (...); Sanz, G
Meeting Abstract. 10.1016/S0145-2126(17)30232-1. 2017
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*
Triguero, A.; (...); Sanz, G.
Article. 10.1016/j.leukres.2022.106836. 2022
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147769. 2021
RESULTS OF HLA IDENTICAL ALLOGENIC TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HAPLOIDENTIAL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE OF THE SPANISH HAEMATOPOIETIC TRANSPLANT GROUP (GETH)
Almorox Rebeca, Bailen; (...); Mi, Kwon
Meeting Abstract. 2021
Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation
Letter. 10.1016/j.transci.2019.02.002. 2019
Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.
Montoro, Juan; (...); Pinana, Jose Luis
Letter. 10.1038/s41409-020-01161-1. 2020
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib
Such, E; (...); Cervera, J
Article. 10.1159/000497348. 2019
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Article. 10.1038/s41409-023-01949-x. 2023
Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
Mussetti, Alberto; (...); Sureda, Anna
Meeting Abstract. 10.1182/blood-2022-160000. 2022
Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.
Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A
Review. 10.3389/fonc.2021.614215. 2021
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
Escamilla Gómez V; (...); Pérez-Simón JA
Article. 10.1038/s41409-019-0731-x. 2020
Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.; (...); Garcia-Manero, Guillermo
Meeting Abstract. 10.1182/blood-2021-145626. 2021
SAFETY AND EFFECTIVENESS OF ASCIMINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER FAILURE OF VARIOUS TYROSINE KINASE INHIBITORS
Luna, de Abia Alejandro; (...); Garcia, Gutierrez Valentin
Meeting Abstract. 2020
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V; (...); Hernández-Boluda JC
Letter. 10.1038/s41408-021-00420-8. 2021
Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL
Yanez, L; (...); Bosch, F
Meeting Abstract. 2019
Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.
Article. 10.1111/ajt.14580. 2018
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Moles-Poveda, P; (...); Botella-Estrada, R
Article. 10.1016/j.ad.2017.11.003. 2018
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using PostTransplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-180075. 2023
Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation.
Piñana JL; (...); Infectious Diseases Working Party of the European Society for Blood and Marrow T
Article. 10.1093/infdis/jiaa553. 2020
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Kharfan-Dabaja, MA; (...); Mohty, M
Article. 10.1111/bjh.17426. 2021
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
Secondary neoplasms after umbilical cord blood transplantation. On behalf of eurocord and the european group for blood and marrow transplantation
El Ayoubi, H. Rafii; (...); Gluckman, E.
Meeting Abstract. 2022
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.
Kharfan-Dabaja, Mohamed A.; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000920. 2023
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT
Baron, F; (...); Nagler, A
Article. 10.1186/s13045-017-0497-9. 2017
Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia.
Sanz, J; (...); Grp Espanol Trasplante
Article. 10.1182/bloodadvances.2017006999. 2017
SINTRA-REV CLINICAL TRIAL: PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY AT WEEK 12 OF TREATMENT IN MDS DEL(5Q) AND TRANSFUSION INDEPENDENCE
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 2017
Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.
Hernani, Rafael; (...); Solano, Carlos
Article. 10.1002/jha2.183. 2021
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Palomo L; (...); Such E
Article. 10.1111/bjh.16175. 2020
Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with ß-thalassemia.
Bardón-Cancho EJ; (...); Cela E
Article. 10.1007/s00277-024-05694-z. 2024
Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient.
Sahuquillo-Arce JM; (...); López-Hontangas JL
Article. 10.1099/ijsem.0.005805. 2023
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.
Zeidan AM; (...); Santini V
Article. 10.2217/fon-2022-1237. 2023
STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY
Ibanez, M; (...); Sanz, G
Meeting Abstract. 2017
STUDY OF THE CELL POPULATIONS INFUSED IN THE TRANSPLANT ALOGENICO OF BROTHER HLA-IDENTICAL
Villalba, A.; (...); Sanz, M. A.
Meeting Abstract. 2017
STUDY OF THE EFFECTIVENESS OF IMATINIB IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN A SERIES OF 19 CASES
Poveda, PM; (...); Caballer, JS
Meeting Abstract. 2017
STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
Agula, S.; (...); Ferrer-Marin, F.
Meeting Abstract. 2021
STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS
Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente
Meeting Abstract. 2020
SUPERIORITY OF THE BIOPSY OF BONE MARROW ON PET/TC IN THE PREDICTION OF THE FREE SURVIVAL OF PROGRESSION IN DIFFUSE LINFOMA B OF BIG CELL
Liang, THC; (...); Ortuno, F.
Meeting Abstract. 2017
Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes
Mosquera Orgueira, Adrian; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-159429. 2022
SUSPENSION OF TREATMENT WITH BCR-ABL INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
Galan, IP; (...); Boluda, JCH
Meeting Abstract. 2017
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
T lymphocytes as therapeutic arsenal for patients with hematological malignancies
Montoro, J; (...); Guerreiro, M
Review. 10.1097/CCO.0000000000000481. 2018
T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
Table 1. Clinical-biological and molecular characteristics of CML patients in each group evaluated
Agula, S.; (...); Ferrer-Marin, F.
Meeting Abstract. 2021
TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
Swoboda, R.; (...); Mohty, M.
Meeting Abstract. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.
Piñana J; (...); Sanz J
Article. 10.1016/j.jinf.2019.12.022. 2020
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation.
Shouval R; (...); Nagler A
Meeting Abstract. 10.1182/blood-2019-123310. 2019
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS
Xicoy, Blanca; (...); Sanz, Guillermo
Letter. 10.1016/j.leukres.2018.05.003. 2018
The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.
Piñana JL; (...); Navarro D
Article. 10.1038/s41409-019-0698-7. 2020
The Impact of Cytogenetic Risk on Outcome of Non-T Cell Depleted Haploidentical Stem Cell Transplantation in Relapsed/Refractory AML: A Study From The ALWP/EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2021
The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and CoOccurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party
Dalle, Abou; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-179531. 2023
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
Kanda, Junya; (...); Gluckman, Eliane
Article. 10.1038/s41409-021-01479-4. 2022
The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2021
The modular network structure of the mutational landscape of Acute Myeloid Leukemia
Ibanez, M; (...); Cervera, J
Article. 10.1371/journal.pone.0202926. 2018
The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma.
Schumacher-Kuckelkorn R; (...); Berthold F
Article. 10.1002/pbc.28819. 2021
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose
Article. 10.3390/cancers16244189. 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus
Torrent-Farnell, J; (...); Lizan, L
Article. 10.1016/j.healthpol.2018.03.002. 2018
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
Kuendgen, A; (...); Sanz, G
Meeting Abstract. 10.1182/blood-2018-99-118215. 2018
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A; (...); Sanz G
Article. 10.1038/s41375-020-0917-7. 2020
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Eder S; (...); Nagler A
Article. 10.1002/ajh.24823. 2017
Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt
Battipaglia, G.; (...); Mohty, M.
Meeting Abstract. 2022
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia, Giorgia; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2023.09.028. 2024
Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
Aguila, Sonia; (...); Ferrer Marin, Francisca
Meeting Abstract. 10.1182/blood-2022-163070. 2022
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Benzaquen, Ana; (...); Solano, Carlos
Article. 10.1038/s41409-023-02114-0. 2024
TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY
Hernani, Rafael; (...); Solano, Carlos
Meeting Abstract. 2023
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Article. 10.1038/s41409-024-02298-z. 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Efficace, Fabio; (...); Zeidan, Amer M
Article. 10.1002/hem3.69. 2024
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin
Article. 10.3390/cancers15041045. 2023
Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
Perez-Lamas, Lucia; (...); Garcia Gutierrez, Valentin
Meeting Abstract. 10.1182/blood-2022-167453. 2022
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion
Montoro Gomez, Maria Julia; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-165257. 2022
TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION
Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V
Meeting Abstract. 2019
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.
Crisà E; (...); Santini V
Article. 10.1038/s41375-024-02360-1. 2024
Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Solves P; (...); Carpio N
Article. 10.1016/j.transci.2019.09.011. 2020
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Diez-Campelo, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2021-146019. 2021
Trends and Predictive Factors for Outcome of Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoeitic Cell Transplant: Improved Survival for Young Patients in Recent Years
Bazarbachi, A; (...); Mohty, M
Meeting Abstract. 2020
TRENDS IN THE USE OF HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Giebel, Sebastian; (...); Ciceri, Fabio
Meeting Abstract. 10.1007/s00277-019-03771-2. 2024
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-182949. 2023
Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord
Baron, Frederic; (...); Nagler, Arnon
Meeting Abstract. 2018
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Baron, F; (...); Nagler, A
Article. 10.1038/s41408-019-0204-x. 2019
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
Article. 10.1038/s41409-020-0921-6. 2020
UNRELATED DONOR SELECTION FOR STEM CELL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2024
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed, Rama; (...); Mohty, Mohamad
Article. 10.1002/cncr.34843. 2023
Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bua, BR; (...); Garcia-Sancho, AM
Meeting Abstract. 2021
Upper and/or Lower Respiratory Tract Infection Caused by Human Coronavirus After Allogeneic Stem Cell Transplantation
Pinana, JL; (...); Styczynski, J
Meeting Abstract. 2020
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
USE OF CRISPR/CAS9 TECHNOLOGY TO MODIFY THE IDH2 GENE IN BOTH IN-VIVO AND IN-VITRO MODELS
Gonzalez Romero, E.; (...); Cervera, J., V
Meeting Abstract. 2018
Use of optical genome mapping in the cytogenetic diagnosis of multiple myeloma
de la Rubia, Javier; (...); Such, Esperanza
Meeting Abstract. 2023
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
VALIDATION OF A PANEL OF GENES BY MASSIVE SEQUENCING FOR THE SCREENING OF GERMINAL MUTATIONS IN GENES ASSOCIATED WITH HEREDITARY MYELOID NEOPLASMS
Ibanez, M.; (...); Cervera, J., V
Meeting Abstract. 2019
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Mosquera Orgueira, Adrian; (...); Valcarcel, David
Article. 10.1111/bjh.19341. 2024
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
WHAT IS THE OUTCOME OF PATIENTS IN THE INTERMEDIATE IPSS-R SCORE GROUP? SPANISH APPROACH FOR BETTER STRATIFICATION WITH CLASSICAL TOOLS
Guijo, AMR; (...); Diez-Campelo, M
Meeting Abstract. 10.1016/S0145-2126(17)30374-0. 2017
Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/blood.2023023697. 2024